Although the role of STAT3 in pancreatic cancer aggressiveness [46–48] and the effectiveness of STAT3 signal-inhibiting agents [49, 50] have previously been demonstrated, this is the first study to our knowledge to address the role and the potential therapeutic application of the p38-JAK-STAT3 pathway in pancreatic cancer therapy. The gene discussed is STAT3; the disease is familial pancreatic carcinoma.